NCT06229366
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06229366
Title [Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer (ACCEL)
Acronym ACCEL
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Eli Lilly and Company
Indications
Therapies
Age Groups: adult | senior
Covered Countries CAN

Facility Status City State Zip Country Details
Juravinski Hamilton L8V 5C2 Canada Details
Jewish General Hospital Montreal H3T 1E2 Canada Details
McGill University Montreal H4A 3J1 Canada Details
Centre Hospitalier Universite de QUEBEC Québec G1J 1Z4 Canada Details
Hopital De Chicoutimi Saguenay G7H 5H6 Canada Details
Princess Margaret Cancer Centre Toronto M5G 2M9 Canada Details
BC Cancer Vancouver Vancouver V5Z4E6 Canada Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field